High-dose cyclophosphamide in patients with operable breast cancer: recombinant human GM-CSF ameliorates drug-induced leukopenia and thrombocytopenia.

Abstract

Seventeen patients with breast cancer (nine patients with 10 ipsilateral metastatic axillary nodes, eight patients with inflammatory breast carcinoma) previously untreated with cytotoxic chemotherapy received high-dose cyclophosphamide, 7 g/sqm (HD-CTX) as initial step of a high-dose sequential chemotherapy program. Eleven patients received also intravenous recombinant human granulocyte macrophage-colony stimulating factor (GM-CSF), 5.5 micrograms/kg per day for 7-14 days after HD-CTX. This growth factor significantly ameliorated leukopenia and thrombocytopenia induced by HD-CTX therapy thus allowing earlier delivery of subsequent courses of chemotherapy.

• Authors: M Bregni, S Siena, F Ravagnani, G Bonadonna, A M Gianni
• Journal: Haematologica (Haematologica) 1990 Jan-Feb Vol. 75 Suppl 1 Pg. 95-8 ISSN: 0390-6078 [Print] Italy
• PMID: 2190885 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Colony-Stimulating Factors
• Growth Substances
• Recombinant Proteins
• Granulocyte-Macrophage Colony-Stimulating Factor
• Cyclophosphamide

Topics

• Adult
• Breast Neoplasms (drug therapy)
• Colony-Stimulating Factors (therapeutic use)
• Cyclophosphamide (administration & dosage, adverse effects)
• Female
• Granulocyte-Macrophage Colony-Stimulating Factor
• Growth Substances (therapeutic use)
• Humans
• Leukopenia (chemically induced, drug therapy)
• Middle Aged
• Recombinant Proteins (therapeutic use)
• Thrombocytopenia (chemically induced, drug therapy)